Advertisement
Canada markets open in 19 minutes

  • S&P/TSX

    21,740.20
    -159.79 (-0.73%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CAD/USD

    0.7235
    -0.0018 (-0.25%)
     

  • CRUDE OIL

    85.03
    -0.38 (-0.44%)
     

  • Bitcoin CAD

    87,232.23
    -4,179.11 (-4.57%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,392.30
    +9.30 (+0.39%)
     

  • RUSSELL 2000

    1,975.71
    -27.47 (-1.37%)
     

  • 10-Yr Bond

    4.6490
    +0.0210 (+0.45%)
     

  • NASDAQ futures

    17,889.25
    +13.00 (+0.07%)
     

  • VOLATILITY

    18.55
    -0.68 (-3.53%)
     

  • FTSE

    7,859.86
    -105.67 (-1.33%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6799
    -0.0025 (-0.37%)
     
BREAKING:

INFLATION IN CANADA UP SLIGHTLY TO 2.9% IN MARCH

On a seasonally adjusted monthly basis, the CPI increased 0.3% last month, says StatCan

Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

Kenneth Smith
Updated
Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.

Continue reading